Headlines about Assembly Biosciences (NASDAQ:ASMB) have been trending somewhat negative on Tuesday, according to AlphaOne Sentiment Analysis. The research group, a division of Accern, identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real-time. AlphaOne ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Assembly Biosciences earned a media sentiment score of -0.22 on AlphaOne’s scale. AlphaOne also gave headlines about the biopharmaceutical company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an effect on the company’s share price in the next several days.

Insider Buying and Selling by Quarter for Assembly Biosciences (NASDAQ:ASMB)

Separately, Chardan Capital started coverage on Assembly Biosciences in a research note on Tuesday, May 30th. They issued a “buy” rating and a $35.00 price objective for the company.

Shares of Assembly Biosciences (ASMB) opened at 21.88 on Tuesday. Assembly Biosciences has a 52 week low of $5.00 and a 52 week high of $28.24. The company has a 50-day moving average price of $23.93 and a 200 day moving average price of $20.67. The stock’s market capitalization is $379.53 million.

ILLEGAL ACTIVITY WARNING: This news story was reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/06/20/assembly-biosciences-asmb-earns-news-sentiment-score-of-0-22.html.

About Assembly Biosciences

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Receive News & Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.